IMCR Corporate Deck January 2026 13Jan2026.pdf

1、Transformative immunomodulating medicines for patientsJanuary 202612Forward Looking StatementsThis presentation contains“forward-looking statements”within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.Words such as“may”,“will”,“believe”,“expect”,“p

2、lan”,“anticipate”,“estimate”,“expect”,“continue”and similar expressions(as well as other words or expressions referencing future events or circumstances)are intended to identify forward-looking statements.All statements,other than statements of historical facts,included in this presentation are forw

3、ard-looking statements.These statements include,but are not limited to,Immunocores capabilities across oncology,autoimmune and infectious disease therapeutic areas and its ability to advance its clinical and pre-clinical pipeline;the estimated market size and patient population for KIMMTRAK and Immu

4、nocores other product candidates;the growth opportunities for KIMMTRAK,including HLA-A02+melanoma,cutaneous melanoma and adjuvant uveal melanoma;expected submission of investigational new drug applications or clinical trial applications;the potential regulatory approval,expected clinical benefits an

5、d availability of Immunocores product candidates;the commercial performance of KIMMTRAK,including Immunocores expectations of moderate revenue growth in 2026;the potential benefits and advantages that KIMMTRAK,brenetafusp and Immunocores other product candidates will provide for patients,alone or in

6、 combination with other therapies;expectations regarding the design,progress,timing,enrollment,scope,expansion,funding,and results of Immunocores existing and planned clinical trials,those of Immunocores collaboration partners or the combined clinical trials with Immunocores collaboration partners;t